Appointment of Joint Broker
October 09 2009 - 5:14AM
UK Regulatory
TIDMIMM
RNS Number : 5242A
Immupharma PLC
09 October 2009
+------------------------------------+------------------------------------+
| FOR IMMEDIATE RELEASE | 9 OCTOBER 2009 |
+------------------------------------+------------------------------------+
ImmuPharma PLC
("ImmuPharma")
Appointment of Joint Broker
ImmuPharma PLC (LSE: IMM) the specialist discovery and development
pharmaceutical company is pleased to announce the appointment of Noble & Company
Limited ("Noble") as its joint broker with immediate effect.
Commenting on Noble's appointment, Richard Warr, Chairman of ImmuPharma said:
"We are delighted to have a team as committed as Noble working with us. Over the
past months they have been instrumental in attracting blue-chip funds onto
ImmuPharma's share register."
- Ends -
For further information please contact:
+----------------------------------------------------+-------------------+
| ImmuPharma PLC | +44 20 7152 4080 |
+----------------------------------------------------+-------------------+
| Dimitri Dimitriou, Chief Executive Officer | |
| Richard Warr, Chairman | |
+----------------------------------------------------+-------------------+
| | |
+----------------------------------------------------+-------------------+
| Buchanan Communications | +44 20 7466 5000 |
+----------------------------------------------------+-------------------+
| Lisa Baderoon | |
+----------------------------------------------------+-------------------+
| | |
+----------------------------------------------------+-------------------+
| Panmure Gordon & Co | +44 151 243 0963 |
| Andrew Burnett | |
| Rakesh Sharma | |
+----------------------------------------------------+-------------------+
| | |
+----------------------------------------------------+-------------------+
| Noble & Company Limited | +44 20 7763 2200 |
+----------------------------------------------------+-------------------+
| James Bromhead | |
| Sam Reynolds | |
+----------------------------------------------------+-------------------+
Notes to Editors
About ImmuPharma PLC
ImmuPharma is a drug discovery and development group with its key operations in
London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company
aims to develop novel drugs to treat serious medical conditions for which there
is a high unmet need. It has five drugs in development to treat 1) Lupus, 2)
Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5)
Inflammatory and Allergic disorders.
Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic,
life-threatening autoimmune disease, was licensed to Cephalon, Inc in a
transaction worth up to $500m in milestone payments in addition to significant
royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m
post year end in Q1 2009
The company also has a strong proprietary and collaborative drug development
pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUKAKRKURRRRA
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
